A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy

Matthew D. Galsky; Noah M. Hahn; Jonathan Rosenberg; Guru Sonpavde; Thomas Hutson; William K. Oh; Robert Dreicer; Nicholas Vogelzang; Cora Sternberg; Dean F. Bajorin; Joaquim Bellmunt

doi:10.1016/S1470-2045(10)70275-8

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy

Matthew D. Galsky, Noah M. Hahn, Jonathan Rosenberg, Guru Sonpavde, Thomas Hutson, William K. Oh, Robert Dreicer, Nicholas Vogelzang, Cora Sternberg, Dean F. Bajorin, Joaquim Bellmunt

Research output: Contribution to journal › Letter › peer-review

168 Scopus citations

Original language	English (US)
Pages (from-to)	211-214
Number of pages	4
Journal	The Lancet Oncology
Volume	12
Issue number	3
DOIs	https://doi.org/10.1016/S1470-2045(10)70275-8
State	Published - Mar 2011
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(10)70275-8

Cite this

@article{450985b1fc44467cb8c270a63c98ba7e,

title = "A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy",

author = "Galsky, {Matthew D.} and Hahn, {Noah M.} and Jonathan Rosenberg and Guru Sonpavde and Thomas Hutson and Oh, {William K.} and Robert Dreicer and Nicholas Vogelzang and Cora Sternberg and Bajorin, {Dean F.} and Joaquim Bellmunt",

note = "Funding Information: DFB has received consultancy fees from Bristol-Myers Squibb and payment for lectures from Eli Lilly. RD has board membership with Transgene and receives consultancy fees from Millennium, Novartis, Centocor Ortho Biotech, GTx, EMD Serano, and Endo Pharmaceuticals. He has received payment for lectures from Sanofi-Aventis and payment for educational presentations from AstraZeneca and the Robert Michael Educational Institute. NMH is a member of the advisory board with Sanofi-Aventis and MethylGene, has research support grants with Celgene, and has received speaker's fees from Sanofi-Aventis. JR has received consultancy fees from Centocor, Genentech, Abbott, Novartis, GlaxoSmithKline, and ImClone. He has grants with Sanofi-Aventis and has received payment for lectures from Novartis. GS has grants with Bellicum Pharmaceuticals, Novartis, Bristol-Myers Squibb, Pfizer, Cephalon, and Celgene. He has received payment for lectures from Sanofi-Aventis, Wyeth, Pfizer, Novartis, and GlaxoSmithKline. MDG has received consultancy fees from GlaxoSmithKline, Bristol-Myers Squibb, and Pfizer. NV has received consultancy fees from Allos, Ambit Bioscience, Amgen, Bayer, Boehringer Ingelheim, Celgene, Clinical Care Options, Cougar Biotechnology/Johnson & Johnson, Dendreon, Eisai, Genentech, GlaxoSmithKline, GPC Biotech, Keryx, Mannkind, Novartis, Onyx, Pfizer, Takeda/Millennium, and Veride. He has received speaker's fees from Ambit Bioscience, Amgen, Arqule, Bayer, Clinical Care Options, Cougar Biotechnology/Johnson & Johnson, Dendreon, Eisai, Imedex, Lilly, Novartis, Onyx, Pfizer, Quintiles, Research to Practice, Sanofi-Aventis, Schering-Plough, Veridex, Wilex, and Wyeth. He has received grants or research support from Algeta, Arqule, AstraZeneca, Bristol-Myers Squibb, Cougar Biotechnology/Johnson & Johnson, GlaxoSmithKline, Mannkind, Novartis, Pfizer, Takeda/Millennium, Tokai, Veridex, and Wilex. TH, WKO, CS, and JB declare no conflicts of interest. Copyright: Copyright 2011 Elsevier B.V., All rights reserved.",

year = "2011",

month = mar,

doi = "10.1016/S1470-2045(10)70275-8",

language = "English (US)",

volume = "12",

pages = "211--214",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "3",

}

TY - JOUR

T1 - A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy

AU - Galsky, Matthew D.

AU - Hahn, Noah M.

AU - Rosenberg, Jonathan

AU - Sonpavde, Guru

AU - Hutson, Thomas

AU - Oh, William K.

AU - Dreicer, Robert

AU - Vogelzang, Nicholas

AU - Sternberg, Cora

AU - Bajorin, Dean F.

AU - Bellmunt, Joaquim

N1 - Funding Information: DFB has received consultancy fees from Bristol-Myers Squibb and payment for lectures from Eli Lilly. RD has board membership with Transgene and receives consultancy fees from Millennium, Novartis, Centocor Ortho Biotech, GTx, EMD Serano, and Endo Pharmaceuticals. He has received payment for lectures from Sanofi-Aventis and payment for educational presentations from AstraZeneca and the Robert Michael Educational Institute. NMH is a member of the advisory board with Sanofi-Aventis and MethylGene, has research support grants with Celgene, and has received speaker's fees from Sanofi-Aventis. JR has received consultancy fees from Centocor, Genentech, Abbott, Novartis, GlaxoSmithKline, and ImClone. He has grants with Sanofi-Aventis and has received payment for lectures from Novartis. GS has grants with Bellicum Pharmaceuticals, Novartis, Bristol-Myers Squibb, Pfizer, Cephalon, and Celgene. He has received payment for lectures from Sanofi-Aventis, Wyeth, Pfizer, Novartis, and GlaxoSmithKline. MDG has received consultancy fees from GlaxoSmithKline, Bristol-Myers Squibb, and Pfizer. NV has received consultancy fees from Allos, Ambit Bioscience, Amgen, Bayer, Boehringer Ingelheim, Celgene, Clinical Care Options, Cougar Biotechnology/Johnson & Johnson, Dendreon, Eisai, Genentech, GlaxoSmithKline, GPC Biotech, Keryx, Mannkind, Novartis, Onyx, Pfizer, Takeda/Millennium, and Veride. He has received speaker's fees from Ambit Bioscience, Amgen, Arqule, Bayer, Clinical Care Options, Cougar Biotechnology/Johnson & Johnson, Dendreon, Eisai, Imedex, Lilly, Novartis, Onyx, Pfizer, Quintiles, Research to Practice, Sanofi-Aventis, Schering-Plough, Veridex, Wilex, and Wyeth. He has received grants or research support from Algeta, Arqule, AstraZeneca, Bristol-Myers Squibb, Cougar Biotechnology/Johnson & Johnson, GlaxoSmithKline, Mannkind, Novartis, Pfizer, Takeda/Millennium, Tokai, Veridex, and Wilex. TH, WKO, CS, and JB declare no conflicts of interest. Copyright: Copyright 2011 Elsevier B.V., All rights reserved.

PY - 2011/3

Y1 - 2011/3

UR - http://www.scopus.com/inward/record.url?scp=79952012493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952012493&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(10)70275-8

DO - 10.1016/S1470-2045(10)70275-8

M3 - Letter

C2 - 21376284

AN - SCOPUS:79952012493

SN - 1470-2045

VL - 12

SP - 211

EP - 214

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 3

ER -

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this